Lilly Dermatology Division?

Quote
anonymous said:
Nice try troll! We are above forecast!
Click to expand...

Haaaa. Right. Cosentyx has better efficacy. It's fully human. That means the body doesn't fight it you idiots. There's more immunogenicity with Taltz, or do you want to deny that? More serious infection rate. Seriously what do you have to gain on cosentyx? Ya'll can just stay home because my friends who sell cosentyx are telling us they are ripping you apart. Btw I sell Humira so you people do not represent any competition or threat to me.
 






You should educate yourself before commenting here.

1) Taltz sets the current record for clearing psoriasis (90% PASI-75). Cosentyx (Novartis drug) is roughly 8-10% points less.

2) While we are discussing efficacy, 70% will achieve PASI-90 and 40% PASI-100 (complete clearing). Taltz is the first psoriasis drug to have PASI-100 results in the label.

3) Taltz at 80mg/dose comfortably fits in a single syringe/pen. This is very different than Cosentyz which is usually dosed at 150mg x 2 injections (300mg) each time.

4) According to the PI, roughly 2% of Taltz patients will develop low titre neutralizing antibodies. Neutralizing antibodies can affect drug concentration and efficacy.

5) The Taltz safety profile is excellent, especially when compared to the TNF antagonists. It is comparable to Cosentyx as is expected since both drugs share the same MOA.

6) Feel free to compare the PIs for both drugs. Especially with regards to efficacy and safety.
 






anonymous said:
You should educate yourself before commenting here.

1) Taltz sets the current record for clearing psoriasis (90% PASI-75). Cosentyx (Novartis drug) is roughly 8-10% points less.

2) While we are discussing efficacy, 70% will achieve PASI-90 and 40% PASI-100 (complete clearing). Taltz is the first psoriasis drug to have PASI-100 results in the label.

3) Taltz at 80mg/dose comfortably fits in a single syringe/pen. This is very different than Cosentyz which is usually dosed at 150mg x 2 injections (300mg) each time.

4) According to the PI, roughly 2% of Taltz patients will develop low titre neutralizing antibodies. Neutralizing antibodies can affect drug concentration and efficacy.

5) The Taltz safety profile is excellent, especially when compared to the TNF antagonists. It is comparable to Cosentyx as is expected since both drugs share the same MOA.

6) Feel free to compare the PIs for both drugs. Especially with regards to efficacy and safety.
Click to expand...


This shows how uneducated you are about the biologic market in psoriasis. First and foremost there are no head to head comparisons...why is this important because you have to look at patient populations! When you cherry pick out patients in order to get better efficacy rates (lower body weights, less comorbidities, etc) you're alleged efficacy will look better.

Obviously, the doctors understand this since no, Taltz is not being written and is by far a terrible disappointment of a launch.

Not to mention there have been at least 2 hospitalization a from sever injection site reactions just on the west coast.
 






anonymous said:
This shows how uneducated you are about the biologic market in psoriasis. First and foremost there are no head to head comparisons...why is this important because you have to look at patient populations! When you cherry pick out patients in order to get better efficacy rates (lower body weights, less comorbidities, etc) you're alleged efficacy will look better.

Obviously, the doctors understand this since no, Taltz is not being written and is by far a terrible disappointment of a launch.

Not to mention there have been at least 2 hospitalization a from sever injection site reactions just on the west coast.
Click to expand...
Thank You for setting the record straight. The poster spoke classic sales and marketing nonsense. I went through the same garbage when we launched Actos, going up against Avandia. Having a statistics background, I cringed at the messages/verbatims we were handed.

Glad I left the industry years ago. By the way, when is the pharma industry going to wake up to the nonsense of p-values?
 






anonymous said:
Thank You for setting the record straight. The poster spoke classic sales and marketing nonsense. I went through the same garbage when we launched Actos, going up against Avandia. Having a statistics background, I cringed at the messages/verbatims we were handed.

Glad I left the industry years ago. By the way, when is the pharma industry going to wake up to the nonsense of p-values?
Click to expand...
Why are you on this board. I thought tou left the industry. Cheap entertainment.
 












anonymous said:
Why are you on this board. I thought tou left the industry. Cheap entertainment.
Click to expand...

Tremendous entertainment value.

http://fivethirtyeight.com/features...-agree-on-its-time-to-stop-misusing-p-values/

"The results can be devastating, said Donald Berry, a bio-statistician at the University of Texas MD Anderson Cancer Center. “Patients with serious diseases have been harmed,” he wrote in a commentary published today. “Researchers have chased wild geese, finding too often that statistically significant conclusions could not be reproduced.” Faulty statistical conclusions, he added, have real economic consequences."
-------------------------------------------------------------------------------------------------
The ASA statement’s Principle No. 2: “P-values do not measure the probability that the studied hypothesis is true, or the probability that the data were produced by random chance alone.”

Nor can a p-value tell you the size of an effect, the strength of the evidence or the importance of a result. Yet despite all these limitations, p-values are often used as a way to separate true findings from spurious ones, and that creates perverse incentives.
 






anonymous said:
You should educate yourself before commenting here.

1) Taltz sets the current record for clearing psoriasis (90% PASI-75). Cosentyx (Novartis drug) is roughly 8-10% points less.

2) While we are discussing efficacy, 70% will achieve PASI-90 and 40% PASI-100 (complete clearing). Taltz is the first psoriasis drug to have PASI-100 results in the label.

3) Taltz at 80mg/dose comfortably fits in a single syringe/pen. This is very different than Cosentyz which is usually dosed at 150mg x 2 injections (300mg) each time.

4) According to the PI, roughly 2% of Taltz patients will develop low titre neutralizing antibodies. Neutralizing antibodies can affect drug concentration and efficacy.

5) The Taltz safety profile is excellent, especially when compared to the TNF antagonists. It is comparable to Cosentyx as is expected since both drugs share the same MOA.

6) Feel free to compare the PIs for both drugs. Especially with regards to efficacy and safety.
Click to expand...


PASI 100 is great...but it doesn't mean the patient is 100% clear. It's very misleading. Also, Taltz is the first to have it in their label because when Enbrel, Humira and Stelara came out, PASI 100's weren't allowed in PI's. At that time, the FDA said it would imply that the drug cured psoriasis, which they don't. Since then, the FDA has changed their minds and allowed PASI 100. They only recently even allowed PASI 90 in marketing.

That's not to say the other drugs don't have PASI 100 scores, they do, they just can't market them but the MSL's can.
 






I add Otezla to Cosentyx and get PASI-100s in about 85% of patients at 12 weeks. Around 26 weeks, I start expanding the interval between Cosentyx doses. I've been able to stop it entirely in about half of my patients. About 10% saw some rebound.
 






anonymous said:
PASI 100 is great...but it doesn't mean the patient is 100% clear. It's very misleading. Also, Taltz is the first to have it in their label because when Enbrel, Humira and Stelara came out, PASI 100's weren't allowed in PI's. At that time, the FDA said it would imply that the drug cured psoriasis, which they don't. Since then, the FDA has changed their minds and allowed PASI 100. They only recently even allowed PASI 90 in marketing.

That's not to say the other drugs don't have PASI 100 scores, they do, they just can't market them but the MSL's can.
Click to expand...
Bla bla bla, nice try, cry me a river.
 






anonymous said:
You should educate yourself before commenting here.

1) Taltz sets the current record for clearing psoriasis (90% PASI-75). Cosentyx (Novartis drug) is roughly 8-10% points less.

2) While we are discussing efficacy, 70% will achieve PASI-90 and 40% PASI-100 (complete clearing). Taltz is the first psoriasis drug to have PASI-100 results in the label.

3) Taltz at 80mg/dose comfortably fits in a single syringe/pen. This is very different than Cosentyz which is usually dosed at 150mg x 2 injections (300mg) each time.

4) According to the PI, roughly 2% of Taltz patients will develop low titre neutralizing antibodies. Neutralizing antibodies can affect drug concentration and efficacy.

5) The Taltz safety profile is excellent, especially when compared to the TNF antagonists. It is comparable to Cosentyx as is expected since both drugs share the same MOA.

6) Feel free to compare the PIs for both drugs. Especially with regards to efficacy and safety.
Click to expand...
 






anonymous said:
You should educate yourself before commenting here.

1) Taltz sets the current record for clearing psoriasis (90% PASI-75). Cosentyx (Novartis drug) is roughly 8-10% points less.

2) While we are discussing efficacy, 70% will achieve PASI-90 and 40% PASI-100 (complete clearing). Taltz is the first psoriasis drug to have PASI-100 results in the label.

3) Taltz at 80mg/dose comfortably fits in a single syringe/pen. This is very different than Cosentyz which is usually dosed at 150mg x 2 injections (300mg) each time.

4) According to the PI, roughly 2% of Taltz patients will develop low titre neutralizing antibodies. Neutralizing antibodies can affect drug concentration and efficacy.

5) The Taltz safety profile is excellent, especially when compared to the TNF antagonists. It is comparable to Cosentyx as is expected since both drugs share the same MOA.

6) Feel free to compare the PIs for both drugs. Especially with regards to efficacy and safety.
Click to expand...

Good plan!
"Dr. yes it's the same exact pathway as Cosentyx but it works better because we have RAT - it'll be like the good 'ol days with Remicade except you won't make any $$$. And never mind the ever-increasing doses of MTX you'll have to use in order to keep NA's at bay. Safety? Well it's the same as Cosentyx except for the INJECTION SITE REACTIONS, >20% IMMUNOGENICITY (RAT), THROMBO, NEUTRO...

"What? Sounds like a dirty version of Cosentyx? But we have RAT & you know what they say - 'Get RAT, it does the immune system good.'"
 






Whats salary range and average bonus for Derm? Looks like DC territory is open.
What happened with rep?
DM a micromanager?
Single rep territory or pods?

Thanks in advance
 


















DO NOT COME TO THIS DIVISION!!! Brand and marketing team ruined launch, clueless about the derm space. Company places the worst of the worst DM's in derm and then selected the most incompetent leader DW to lead this tiny division.
Launch was embarrassing, managers are puppets and worst of worst of lilly, which is really saying something.
If u have PhD in ass kissing, this is the place for you, if you are a great rep who focuses on selling and not kissing ass everyday, go somewhere else.
 


















anonymous said:
DO NOT COME TO THIS DIVISION!!! Brand and marketing team ruined launch, clueless about the derm space. Company places the worst of the worst DM's in derm and then selected the most incompetent leader DW to lead this tiny division.
Launch was embarrassing, managers are puppets and worst of worst of lilly, which is really saying something.
If u have PhD in ass kissing, this is the place for you, if you are a great rep who focuses on selling and not kissing ass everyday, go somewhere else.
Click to expand...

This is true across any division in Lilly. For pretty much any launch. Probably really bad in R and D.
 






Pete Salz staffed the entire organization. He should be accountable for the sales leadership team. Sales director and managers were selected over internal leaders with track records of success.
 






Top Bottom
Back
Quote